Atossa Therapeutics, Inc.
ATOS
$0.83
-$0.08-8.82%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 9.69% | 8.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.33% | 21.93% | |||
| Operating Income | -2.33% | -21.93% | |||
| Income Before Tax | -3.19% | -25.38% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -3.19% | -25.38% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3.19% | -25.38% | |||
| EBIT | -2.33% | -21.93% | |||
| EBITDA | -2.34% | -21.94% | |||
| EPS Basic | -3.22% | -25.38% | |||
| Normalized Basic EPS | -3.19% | -25.54% | |||
| EPS Diluted | -3.22% | -25.38% | |||
| Normalized Diluted EPS | -3.19% | -25.54% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||